Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
NYSE COMPOSITE INDX
Gold
Crude Oil
Corcept Begins Recovery After Disastrous Launch Of Korlym
By:
Stock Market News & Stocks to Watch from StraightStocks
Posted on January 08, 2013 at 08:19 AM EST
Last year, the drug developer Corcept Therapeutics (NASDAQ: CORT) received FDA approval for their flagship product Korlym (mifepristone) for the treatment of Cushing’s syndrome.
Related Stocks:
Corcept Therapeutics, Inc.
Stock Market XML and JSON Data API
provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays.
Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Press Release Service
provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates
Bots go here